For instance, recent findings by Cosset and colleagues, unveiled that the effectiveness of αvβ3 antagonists (such as cilengitide or LM609) in GBM models is confined to tumors reliant on GLUT3 (glucose transporter 3)-dependent glucose uptake (32). The gene discussed is SLC2A3; the disease is glioblastoma.